A Systems Biology Preview of the Relationships Between Mineral and Metabolic Complications in Chronic Kidney Disease

Seminars in Nephrology

Volumn 33, Issue 2, 2013, Pages 130-142

  Quarles, L Darryl ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

1,25(OH)2D; Bone; Calcium; Cyp24; Cyp27b1; FGF23; Kidney; Klotho; Osteoblasts (Obs); Osteocytes; PTH

Indexed keywords

CALCITRIOL; FIBROBLAST GROWTH FACTOR 23; G PROTEIN COUPLED RECEPTOR; GLUCOCORTICOID; GLUCOSE; INSULIN; LEPTIN; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE; PROTEIN GPRC6A; SEX HORMONE; UNCLASSIFIED DRUG; VITAMIN D;

ARTICLE; BONE MASS; BONE METABOLISM; BONE REMODELING; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; ENERGY METABOLISM; GLUCOSE HOMEOSTASIS; HORMONE SYNTHESIS; HUMAN; HYPOPHOSPHATEMIA; METABOLIC DISORDER; METABOLIC REGULATION; MINERAL DEFICIENCY; MINERALIZATION; MOLECULAR BIOLOGY; MORTALITY; NONHUMAN; PHOSPHATE METABOLISM; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SECONDARY HYPERPARATHYROIDISM; SIGNAL TRANSDUCTION; UREMIA; VITAMIN D METABOLISM;

ANIMALS; BONE DISEASES, METABOLIC; FIBROBLAST GROWTH FACTORS; HUMANS; OSTEOBLASTS; OSTEOCALCIN; OSTEOCYTES; PARATHYROID HORMONE; PHOSPHATES; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; SYSTEMS BIOLOGY; VITAMIN D;

EID: 84875254011     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2012.12.014     Document Type: Article

References (121)

1. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
2. Meier-Kriesche H.U., Schold J.D., Srinivas T.R., Reed A., Kaplan B. Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant 2004, 4:1662-1668.
3. Kalantar-Zadeh K., Shah A., Duong U., Hechter R.C., Dukkipati R., Kovesdy C.P. Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kidney Int Suppl 2010, 117:S10-S21.
4. Block G.A., Port F.K. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000, 35:1226-1237.
5. Parker B.D., Schurgers L.J., Brandenburg V.M., Christenson R.H., Vermeer C., Ketteler M., et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010, 152:640-648.
6. Teng M., Wolf M., Lowrie E., Ofsthun N., Lazarus J.M., Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003, 349:446-456.
7. Di Iorio B., Bellasi A., Russo D. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 2012, 7:487-493.
8. Quarles L.D. The bone and beyond: 'Dem bones' are made for more than walking. Nat Med 2011, 17:428-430.
9. Goltzman D., Miao D., Panda D.K., Hendy G.N. Effects of calcium and of the Vitamin D system on skeletal and calcium homeostasis: lessons from genetic models. J Steroid Biochem Mol Biol 2004, 89-90:485-489.
10. Messer H.H., Yuen S.Y., Copp D.H. Net uptake and release of calcium and phosphate by bone in vitro: effects of medium calcium and phosphate concentrations. Calcif Tissue Res 1975, 19:1-7.
11. Ferron M., Wei J., Yoshizawa T., Del Fattore A., DePinho R.A., Teti A., et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 2010, 142:296-308.
12. Clemens T.L., Karsenty G. The osteoblast: an insulin target cell controlling glucose homeostasis. J Bone Miner Res 2011, 26:677-680.
13. Pi M., Wu Y., Quarles L.D. GPRC6A mediates responses to osteocalcin in beta-cells in vitro and pancreas in vivo. J Bone Miner Res 2011, 26:1680-1683.
14. Yamashita T., Yoshioka M., Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 2000, 277:494-498.
15. Urakawa I., Yamazaki Y., Shimada T., Iijima K., Hasegawa H., Okawa K., et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006, 444:770-774.
16. Yu X., Ibrahimi O.A., Goetz R., Zhang F., Davis S.I., Garringer H.J., et al. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 2005, 146:4647-4656.
17. Kurosu H., Ogawa Y., Miyoshi M., Yamamoto M., Nandi A., Rosenblatt K.P., et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006, 281:6120-6123.
18. Liu S., Guo R., Simpson L.G., Xiao Z.S., Burnham C.E., Quarles L.D. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 2003, 278:37419-37426.
19. Liu S., Zhou J., Tang W., Jiang X., Rowe D.W., Quarles L.D. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 2006, 291:E38-E49.
20. Stubbs J., Liu S., Quarles L.D. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial 2007, 20:302-308.
21. Shimada T., Kakitani M., Yamazaki Y., Hasegawa H., Takeuchi Y., Fujita T., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004, 113:561-568.
22. Shimada T., Mizutani S., Muto T., Yoneya T., Hino R., Takeda S., et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001, 98:6500-6505.
23. White K.E., Carn G., Lorenz-Depiereux B., Benet-Pages A., Strom T.M., Econs M.J. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001, 60:2079-2086.
24. Shimada T., Yamazaki Y., Takahashi M., Hasegawa H., Urakawa I., Oshima T., et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 2005, 289:F1088-F1095.
25. Bai X., Miao D., Li J., Goltzman D., Karaplis A.C. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 2004, 145:5269-5279.
26. Larsson T., Marsell R., Schipani E., Ohlsson C., Ljunggren O., Tenenhouse H.S., et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 2004, 145:3087-3094.
27. Fukumoto S., Yamashita T. Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin. Curr Opin Nephrol Hypertens 2002, 11:385-389.
28. Benet-Pages A., Orlik P., Strom T.M., Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005, 14:385-390.
29. Larsson T., Davis S.I., Garringer H.J., Mooney S.D., Draman M.S., Cullen M.J., et al. Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed. Endocrinology 2005, 146:3883-3891.
30. Sitara D., Razzaque M.S., St-Arnaud R., Huang W., Taguchi T., Erben R.G., et al. Genetic ablation of vitamin d activation pathway reverses biochemical and skeletal anomalies in fgf-23-null animals. Am J Pathol 2006, 169:2161-2170.
31. Sitara D., Razzaque M.S., Hesse M., Yoganathan S., Taguchi T., Erben R.G., et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 2004, 23:421-432.
32. Kato K., Jeanneau C., Tarp M.A., Benet-Pages A., Lorenz-Depiereux B., Bennett E.P., et al. Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem 2006, 281:18370-18377.
33. Liu S., Tang W., Zhou J., Stubbs J.R., Luo Q., Pi M., et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006, 17:1305-1315.
34. Kolek O.I., Hines E.R., Jones M.D., LeSueur L.K., Lipko M.A., Kiela P.R., et al. 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 2005, 289:G1036-G1042.
35. Weber T.J., Liu S., Indridason O.S., Quarles L.D. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 2003, 18:1227-1234.
36. Isakova T., Gutierrez O.M., Smith K., Epstein M., Keating L.K., Juppner H., et al. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant 2011, 26:584-591.
37. Oliveira R.B., Cancela A.L., Graciolli F.G., Dos Reis L.M., Draibe S.A., Cuppari L., et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?. Clin J Am Soc Nephrol 2010, 5:286-291.
38. Moe S.M., Zidehsarai M.P., Chambers M.A., Jackman L.A., Radcliffe J.S., Trevino L.L., et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol 2011, 6:257-264.
39. Nagano N., Miyata S., Abe M., Kobayashi N., Wakita S., Yamashita T., et al. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int 2006, 69:531-537.
40. Saito H., Maeda A., Ohtomo S., Hirata M., Kusano K., Kato S., et al. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 2005, 280:2543-2549.
41. Liu S., Tang W., Fang J., Ren J., Li H., Xiao Z., et al. Novel regulators of Fgf23 expression and mineralization in Hyp bone. Mol Endocrinol 2009, 23:1505-1518.
42. Martin A., David V., Quarles L.D. Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev 2012, 92:131-155.
43. Quarles L.D. Evidence for a bone-kidney axis regulating phosphate homeostasis. J Clin Invest 2003, 112:642-646.
44. Feng J.Q., Ward L.M., Liu S., Lu Y., Xie Y., Yuan B., et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006, 38:1310-1315.
45. Rowe P.S., Kumagai Y., Gutierrez G., Garrett I.R., Blacher R., Rosen D., et al. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 2004, 34:303-319.
46. Liu S., Rowe P.S., Vierthaler L., Zhou J., Quarles L.D. Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity. J Endocrinol 2007, 192:261-267.
47. Ben-Dov I.Z., Galitzer H., Lavi-Moshayoff V., Goetz R., Kuro-o M., Mohammadi M., et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007, 117:4003-4008.
48. Kuro-o M., Matsumura Y., Aizawa H., Kawaguchi H., Suga T., Utsugi T., et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997, 390:45-51.
49. Li S.A., Watanabe M., Yamada H., Nagai A., Kinuta M., Takei K. Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct Funct 2004, 29:91-99.
50. Zhang F., Zhai G., Kato B.S., Hart D.J., Hunter D., Spector T.D., et al. Association between KLOTHO gene and hand osteoarthritis in a female Caucasian population. Osteoarthritis Cartilage 2007, 15:624-629.
51. Galitzer H., Ben-Dov I.Z., Silver J., Naveh-Many T. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 2010, 77:211-218.
52. Komaba H., Fukagawa M. FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney Int 2010, 77:292-298.
53. Brown W.W., Juppner H., Langman C.B., Price H., Farrow E.G., White K.E., et al. Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen's metaphyseal chondrodysplasia. J Clin Endocrinol Metab 2009, 94:17-20.
54. Kawata T., Imanishi Y., Kobayashi K., Miki T., Arnold A., Inaba M., et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 2007, 18:2683-2688.
55. Lavi-Moshayoff V., Wasserman G., Meir T., Silver J., Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 2010, 299:F882-F889.
56. Sato T., Tominaga Y., Ueki T., Goto N., Matsuoka S., Katayama A., et al. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 2004, 44:481-487.
57. Rhee Y., Bivi N., Farrow E., Lezcano V., Plotkin L.I., White K.E., et al. Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone 2011, 49:636-643.
58. Kobayashi K., Imanishi Y., Miyauchi A., Onoda N., Kawata T., Tahara H., et al. Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur J Endocrinol 2006, 154:93-99.
59. Rhee Y., Allen M.R., Condon K., Lezcano V., Ronda A.C., Galli C., et al. PTH receptor signaling in osteocytes governs periosteal bone formation and intra-cortical remodeling. J Bone Miner Res 2011, 26:1035-1046.
60. Saji F., Shiizaki K., Shimada S., Okada T., Kunimoto K., Sakaguchi T., et al. Regulation of fibroblast growth factor 23 production in bone in uremic rats. Nephron Physiol 2009, 111:59-66.
61. Samadfam R., Richard C., Nguyen-Yamamoto L., Bolivar I., Goltzman D. Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology 2009, 150:4835-4845.
62. Tebben P.J., Singh R.J., Clarke B.L., Kumar R. Fibroblast growth factor 23, parathyroid hormone, and 1alpha,25-dihydroxyvitamin D in surgically treated primary hyperparathyroidism. Mayo Clin Proc 2004, 79:1508-1513.
63. Yu X., Sabbagh Y., Davis S.I., Demay M.B., White K.E. Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations. Bone 2005, 36:971-977.
64. Gutierrez OM, Smith KT, Barchi-Chung A, Patel NM, Isakova T, Wolf M. (1-34) parathyroid hormone infusion acutely lowers fibroblast growth factor 23 concentrations in adult volunteers. Clin J Am Soc Nephrol. 201;7:139-45.
65. Pi M., Zhang L., Lei S.F., Huang M.Z., Zhu W., Zhang J., et al. Impaired osteoblast function in GPRC6A null mice. J Bone Miner Res 2010, 25:1092-1102.
66. Pi M., Quarles L.D. GPRC6A regulates prostate cancer progression. Prostate 2012, 72:399-409.
67. Oury F., Sumara G., Sumara O., Ferron M., Chang H., Smith C.E., et al. Endocrine regulation of male fertility by the skeleton. Cell 2011, 144:796-809.
68. Lee N.K., Sowa H., Hinoi E., Ferron M., Ahn J.D., Confavreux C., et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007, 130:456-469.
69. Pi M., Wu Y., Quarles L.D. GPRC6A mediates responses to osteocalcin in beta-cells in vitro and pancreas in vivo. J Bone Miner Res 2011, 26:1680-1683.
70. Bodine P.V., Komm B.S. Evidence that conditionally immortalized human osteoblasts express an osteocalcin receptor. Bone 1999, 25:535-543.
71. Ferron M., McKee M.D., Levine R.L., Ducy P., Karsenty G. Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice. Bone 2012, 50:568-575.
72. Hinoi E., Gao N., Jung D.Y., Yadav V., Yoshizawa T., Myers M.G., et al. The sympathetic tone mediates leptin's inhibition of insulin secretion by modulating osteocalcin bioactivity. J Cell Biol 2008, 183:1235-1242.
73. Pi M., Parrill A.L., Quarles L.D. GPRC6A mediates the non-genomic effects of steroids. J Biol Chem 2010, 285:39953-39964.
74. Grillo M.L., Jacobus A.P., Scalco R., Amaral F., Rodrigues D.O., Loss E.S., et al. Testosterone rapidly stimulates insulin release from isolated pancreatic islets through a non-genomic dependent mechanism. Horm Metab Res 2005, 37:662-665.
75. Pi M., Faber P., Ekema G., Jackson P.D., Ting A., Wang N., et al. Identification of a novel extracellular cation-sensing G-protein-coupled receptor. J Biol Chem 2005, 280:40201-40209.
76. Rasschaert J., Malaisse W.J. Expression of the calcium-sensing receptor in pancreatic islet B-cells. Biochem Biophys Res Commun 1999, 264:615-618.
77. Ozbek M., Erdogan M., Karadeniz M., Cetinkalp S., Ozgen A.G., Saygili F., et al. Evaluation of beta cell dysfunction by mixed meal tolerance test and oral L-arginine in patients with newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2009, 117:573-576.
78. Pitteloud N., Hardin M., Dwyer A.A., Valassi E., Yialamas M., Elahi D., et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 2005, 90:2636-2641.
79. Kirmani S., Atkinson E.J., Melton L.J., Riggs B.L., Amin S., Khosla S. Relationship of testosterone and osteocalcin levels during growth. J Bone Miner Res 2011, 26:2212-2216.
80. Karsenty G., Ferron M. The contribution of bone to whole-organism physiology. Nature 2012, 481:314-320.
81. Tsuji K., Maeda T., Kawane T., Matsunuma A., Horiuchi N. Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D3 synthesis in leptin-deficient mice. J Bone Miner Res 2010, 25:1711-1723.
82. Cheung W., Yu P.X., Little B.M., Cone R.D., Marks D.L., Mak R.H. Role of leptin and melanocortin signaling in uremia-associated cachexia. J Clin Invest 2005, 115:1659-1665.
83. Kalbacher E., Koppe L., Zarrouki B., Pillon N.J., Fouque D., Soulage C.O. Human uremic plasma and not urea induces exuberant secretion of leptin in 3T3-L1 adipocytes. J Ren Nutr 2011, 21:72-75.
84. Bhandaru M., Kempe D.S., Rotte A., Capuano P., Pathare G., Sopjani M., et al. Decreased bone density and increased phosphaturia in gene-targeted mice lacking functional serum- and glucocorticoid-inducible kinase 3. Kidney Int 2011, 80:61-67.
85. Rached M.T., Kode A., Xu L., Yoshikawa Y., Paik J.H., Depinho R.A., et al. FoxO1 is a positive regulator of bone formation by favoring protein synthesis and resistance to oxidative stress in osteoblasts. Cell Metab 2010, 11:147-160.
86. Wojcik M., Dolezal-Oltarzewska K., Janus D., Drozdz D., Sztefko K., Starzyk J.B. FGF23 contributes to insulin sensitivity in obese adolescents-preliminary results. Clin Endocrinol (Oxf) 2012, 77:537-540.
87. Mirza M.A., Alsio J., Hammarstedt A., Erben R.G., Michaelsson K., Tivesten A., et al. Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol 2011, 31:219-227.
88. Li H., Martin A.C., David V., Quarles L.D. Compound deletion of FGFR3 and FGFR4 partially rescues the hyp mouse phenotype. Am J Physiol Endocrinol Metab 2011, 300:E508-E517.
89. Tsujikawa H., Kurotaki Y., Fujimori T., Fukuda K., Nabeshima Y. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 2003, 17:2393-2403.
90. Shiraki-Iida T., Aizawa H., Matsumura Y., Sekine S., Iida A., Anazawa H., et al. Structure of the mouse klotho gene and its two transcripts encoding membrane and secreted protein. FEBS Lett 1998, 424:6-10.
91. Kuro-o M. Klotho. Pflugers Arch 2010, 459:333-343.
92. Gutierrez O., Isakova T., Rhee E., Shah A., Holmes J., Collerone G., et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005, 16:2205-2215.
93. Imanishi Y., Inaba M., Nakatsuka K., Nagasue K., Okuno S., Yoshihara A., et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 2004, 65:1943-1946.
94. Craver L., Marco M.P., Martinez I., Rue M., Borras M., Martin M.L., et al. Mineral metabolism parameters throughout chronic kidney disease stages 1-5-achievement of K/DOQI target ranges. Nephrol Dial Transplant 2007, 22:1171-1176.
95. Stubbs J.R., Idiculla A., Slusser J., Menard R., Quarles L.D. Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol 2010, 21:353-361.
96. Wetmore J.B., Quarles L.D. Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?. Nat Clin Pract Nephrol 2009, 5:24-33.
97. Wetmore J.B., Liu S., Krebill R., Menard R., Quarles L.D. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 2010, 5:110-116.
98. Goebel S., Lienau J., Rammoser U., Seefried L., Wintgens K.F., Seufert J., et al. FGF23 is a putative marker for bone healing and regeneration. J Orthop Res 2009, 27:1141-1146.
99. Gutierrez O.M., Mannstadt M., Isakova T., Rauh-Hain J.A., Tamez H., Shah A., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008, 359:584-592.
100. Fliser D., Kollerits B., Neyer U., Ankerst D.P., Lhotta K., Lingenhel A., et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) study. J Am Soc Nephrol 2007, 18:2600-2608.
101. Eraranta A., Riutta A., Fan M., Koskela J., Tikkanen I., Lakkisto P., et al. Dietary phosphate binding and loading alter kidney angiotensin-converting enzyme mRNA and protein content in 5/6 nephrectomized rats. Am J Nephrol 2012, 35:401-408.
102. Li Y.C., Kong J., Wei M., Chen Z.F., Liu S.Q., Cao L.P. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002, 110:229-238.
103. Thadhani R., Appelbaum E., Pritchett Y., Chang Y., Wenger J., Tamez H., et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012, 307:674-684.
104. Stubbs J.R., Quarles L.D. Fibroblast growth factor 23: uremic toxin or innocent bystander in chronic kidney disease?. Nephrol News Issues 2009, 23:33-34. 36-7.
105. Dilauro M., Zimpelmann J., Robertson S.J., Genest D., Burns K.D. Effect of ACE2 and angiotensin-(1-7) in a mouse model of early chronic kidney disease. Am J Physiol Renal Physiol 2010, 298:F1523-F1532.
106. Nehgme R., Fahey J.T., Smith C., Carpenter T.O. Cardiovascular abnormalities in patients with X-linked hypophosphatemia. J Clin Endocrinol Metab 1997, 82:2450-2454.
107. Faul C., Amaral A.P., Oskouei B., Hu M.C., Sloan A., Isakova T., et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011, 121:4393-4408.
108. Yoon H.E., Ghee J.Y., Piao S., Song J.H., Han D.H., Kim S., et al. Angiotensin II blockade upregulates the expression of Klotho, the anti-ageing gene, in an experimental model of chronic cyclosporine nephropathy. Nephrol Dial Transplant 2011, 26:800-813.
109. Takata R., Akamatsu S., Kubo M., Takahashi A., Hosono N., Kawaguchi T., et al. Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet 2010, 42:751-754.
110. Dehghan A., Dupuis J., Barbalic M., Bis J.C., Eiriksdottir G., Lu C., et al. Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation 2011, 123:731-738.
111. Dehghan A., Kardys I., de Maat M.P., Uitterlinden A.G., Sijbrands E.J., Bootsma A.H., et al. Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes 2007, 56:872-878.
112. Danesh J., Wheeler J.G., Hirschfield G.M., Eda S., Eiriksdottir G., Rumley A., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350:1387-1397.
113. Hwang Y.C., Jeong I.K., Ahn K.J., Chung H.Y. Circulating osteocalcin level is associated with improved glucose tolerance, insulin secretion and sensitivity independent of the plasma adiponectin level. Osteoporos Int 2012, 23:1337-1342.
114. Pi M., Chen L., Huang M.Z., Zhu W., Ringhofer B., Luo J., et al. GPRC6A null mice exhibit osteopenia, feminization and metabolic syndrome. PLoS One 2008, 3:e3858.
115. Pollock N.K., Bernard P.J., Gower B.A., Gundberg C.M., Wenger K., Misra S., et al. Lower uncarboxylated osteocalcin concentrations in children with prediabetes is associated with beta-cell function. J Clin Endocrinol Metab 2011, 96:E1092-E1099.
116. Ferron M., Hinoi E., Karsenty G., Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci U S A 2008, 105:5266-5270.
117. Pittas A.G., Harris S.S., Eliades M., Stark P., Dawson-Hughes B. Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrinol Metab 2009, 94:827-832.
118. Schafer A.L., Sellmeyer D.E., Schwartz A.V., Rosen C.J., Vittinghoff E., Palermo L., et al. Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study). J Clin Endocrinol Metab 2011, 96:E1982-E1989.
119. Schlieper G., Westenfeld R., Kruger T., Cranenburg E.C., Magdeleyns E.J., Brandenburg V.M., et al. Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. J Am Soc Nephrol 2011, 22:387-395.
120. DeFronzo R.A., Alvestrand A., Smith D., Hendler R., Hendler E., Wahren J. Insulin resistance in uremia. J Clin Invest 1981, 67:563-568.
121. Bacchetta J., Boutroy S., Guebre-Egziabher F., Juillard L., Drai J., Pelletier S., et al. The relationship between adipokines, osteocalcin and bone quality in chronic kidney disease. Nephrol Dial Transplant 2009, 24:3120-3125.